FDA warns 350 practices against unapproved versions of Botox

12/28/2012 | Medical News Today

The FDA warned more than 350 medical practices regarding unapproved versions of wrinkle fighter Botox as well as other drugs from Canada Drugs and its subsidiaries. The products could be unsafe, ineffective, counterfeit and contaminated, the FDA said. The FDA asked the practices to stop using the treatments in patients.

View Full Article in:

Medical News Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD